Illumina, Inc. (NASDAQ:ILMN) – Equities research analysts at William Blair issued their Q1 2019 earnings per share estimates for Illumina in a note issued to investors on Tuesday, September 4th. William Blair analyst A. Murphy forecasts that the life sciences company will earn $1.54 per share for the quarter. William Blair also issued estimates for Illumina’s Q2 2019 earnings at $1.56 EPS, Q3 2019 earnings at $1.42 EPS and Q4 2019 earnings at $1.48 EPS.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The company had revenue of $830.00 million during the quarter, compared to analysts’ expectations of $786.88 million. During the same period last year, the firm posted $0.82 earnings per share. The business’s revenue was up 25.4% on a year-over-year basis.
A number of other research firms have also recently issued reports on ILMN. Canaccord Genuity reaffirmed a “buy” rating and issued a $340.00 price objective (up from $330.00) on shares of Illumina in a research report on Friday, July 27th. Deutsche Bank raised their price objective on Illumina from $280.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. BidaskClub raised Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 1st. Citigroup raised their price objective on Illumina from $275.00 to $330.00 and gave the company a “buy” rating in a research report on Monday, June 25th. Finally, Morgan Stanley upgraded Illumina from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $210.00 to $320.00 in a research note on Tuesday, August 7th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $308.25.
ILMN opened at $348.29 on Friday. Illumina has a 12-month low of $196.00 and a 12-month high of $357.93. The company has a market capitalization of $50.91 billion, a PE ratio of 87.07, a price-to-earnings-growth ratio of 2.87 and a beta of 0.97. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22.
In other news, SVP Mostafa Ronaghi sold 10,500 shares of the stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $284.83, for a total transaction of $2,990,715.00. Following the transaction, the senior vice president now owns 81,496 shares in the company, valued at $23,212,505.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Francis A. Desouza sold 2,100 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $276.14, for a total value of $579,894.00. Following the transaction, the chief executive officer now owns 83,282 shares in the company, valued at approximately $22,997,491.48. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,137 shares of company stock worth $13,246,862. 0.54% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. Jennison Associates LLC increased its stake in Illumina by 4.5% during the 2nd quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock worth $1,200,271,000 after acquiring an additional 185,745 shares during the period. Fred Alger Management Inc. increased its stake in Illumina by 21.4% during the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock worth $217,413,000 after acquiring an additional 137,302 shares during the period. American Century Companies Inc. increased its stake in Illumina by 19.2% during the 1st quarter. American Century Companies Inc. now owns 761,796 shares of the life sciences company’s stock worth $180,104,000 after acquiring an additional 122,612 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Illumina by 5.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock worth $168,863,000 after acquiring an additional 31,985 shares during the period. Finally, Millennium Management LLC increased its stake in Illumina by 219.8% during the 2nd quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock worth $153,318,000 after acquiring an additional 377,283 shares during the period. Hedge funds and other institutional investors own 89.78% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: Price to Earnings Ratio (PE)
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.